SLC25A47

Summary

SLC25A47 (solute carrier family 25 member 47, HGNC:20115) is a protein-coding gene on chromosome 14q32.2, encoding Solute carrier family 25 member 47 (Q6Q0C1). Mitochondrial NAD(+) transporter that acts as a ‘metabolic gate’ in hepatic lipogenesis.

This gene encodes a member of a large family of mitochondrial transporters. The nuclear-encoded carrier protein is embedded in the inner mitochondrial membrane. This member of the family is thought to be an uncoupling protein that uncouples mitochondrial respiration from ATP synthesis by dissipating the transmembrane proton gradient. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 283600 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_207117

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20115
Approved symbol	SLC25A47
Name	solute carrier family 25 member 47
Location	14q32.2
Locus type	gene with protein product
Status	Approved
Aliases	HDCMP
Ensembl gene	ENSG00000140107
Ensembl biotype	protein_coding
OMIM	609911
Entrez	283600

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000361529, ENST00000557052

RefSeq mRNA: 2 — MANE Select: NM_207117 NM_001350877, NM_207117

CCDS: CCDS86432, CCDS9959

Canonical transcript exons

ENST00000361529 — 6 exons

Exon	Start	End
ENSE00001337455	100326157	100326228
ENSE00001422253	100329365	100330421
ENSE00002529120	100323339	100323442
ENSE00003511309	100325788	100325831
ENSE00003536317	100328726	100329044
ENSE00003565062	100327188	100327370

Expression profiles

Bgee: expression breadth broad, 49 present calls, max score 98.92.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4962 / max 307.1062, expressed in 9 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141457	0.4962	9

Top tissues by expression

184 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	98.92	gold quality
liver	UBERON:0002107	96.93	gold quality
pancreatic ductal cell	CL:0002079	78.47	silver quality
vena cava	UBERON:0004087	74.49	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	71.60	gold quality
nasal cavity epithelium	UBERON:0005384	71.53	gold quality
lateral nuclear group of thalamus	UBERON:0002736	71.23	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	71.11	gold quality
epithelial cell of pancreas	CL:0000083	70.93	gold quality
tendon of biceps brachii	UBERON:0008188	70.14	gold quality
upper arm skin	UBERON:0004263	70.03	gold quality
parotid gland	UBERON:0001831	69.90	gold quality
body of tongue	UBERON:0011876	69.58	gold quality
kidney epithelium	UBERON:0004819	69.19	gold quality
layer of synovial tissue	UBERON:0007616	67.60	gold quality
buccal mucosa cell	CL:0002336	67.56	gold quality
quadriceps femoris	UBERON:0001377	67.27	gold quality
mammary duct	UBERON:0001765	66.94	gold quality
tongue	UBERON:0001723	66.93	gold quality
epithelium of mammary gland	UBERON:0003244	66.86	gold quality
vastus lateralis	UBERON:0001379	66.69	gold quality
medial globus pallidus	UBERON:0002477	66.45	gold quality
globus pallidus	UBERON:0001875	66.30	gold quality
pons	UBERON:0000988	66.25	gold quality
saphenous vein	UBERON:0007318	66.21	gold quality
cerebellar vermis	UBERON:0004720	66.13	gold quality
dorsal plus ventral thalamus	UBERON:0001897	65.85	gold quality
substantia nigra pars reticulata	UBERON:0001966	65.65	gold quality
trachea	UBERON:0003126	65.64	gold quality
lateral globus pallidus	UBERON:0002476	65.33	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• hepatocellular carcinoma down-regulated mitochondrial carrier protein is a novel liver-specific uncoupling protein (PMID:15322095)
• HDMCP might function through promoting ATP depletion and decreasing H(2)O(2) production. (PMID:19303656)
• Compares and contrasts all the known human SLC25A* genes and includes functional information. (PMID:23266187)
• Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKalpha mediating lipid metabolism and tumorigenesis. (PMID:36804859)
• The human glucose and lipid homeostasis-associated genetic polymorphisms do not regulate SLC25A47 gene expression in the liver. (PMID:37523565)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc25a47a	ENSDARG00000059923
danio_rerio	slc25a47b	ENSDARG00000102071
mus_musculus	Slc25a47	ENSMUSG00000048856
rattus_norvegicus	Slc25a47	ENSRNOG00000003020

Paralogs (49): SLC25A13 (ENSG00000004864), SLC25A5 (ENSG00000005022), SLC25A39 (ENSG00000013306), SLC25A40 (ENSG00000075303), SLC25A3 (ENSG00000075415), SLC25A43 (ENSG00000077713), SLC25A24 (ENSG00000085491), SLC25A1 (ENSG00000100075), SLC25A17 (ENSG00000100372), SLC25A14 (ENSG00000102078), SLC25A15 (ENSG00000102743), SLC25A11 (ENSG00000108528), UCP1 (ENSG00000109424), SLC25A36 (ENSG00000114120), SLC25A12 (ENSG00000115840), SLC25A2 (ENSG00000120329), SLC25A51 (ENSG00000122696), SLC25A16 (ENSG00000122912), SLC25A35 (ENSG00000125434), SLC25A19 (ENSG00000125454), SLC25A23 (ENSG00000125648), SLC25A52 (ENSG00000141437), SLC25A38 (ENSG00000144659), SLC25A26 (ENSG00000144741), SLC25A48 (ENSG00000145832), SLC25A37 (ENSG00000147454), SLC25A25 (ENSG00000148339), SLC25A31 (ENSG00000151475), SLC25A4 (ENSG00000151729), SLC25A27 (ENSG00000153291), SLC25A28 (ENSG00000155287), SLC25A44 (ENSG00000160785), SLC25A45 (ENSG00000162241), SLC25A34 (ENSG00000162461), SLC25A32 (ENSG00000164933), SLC25A6 (ENSG00000169100), SLC25A33 (ENSG00000171612), SLC25A30 (ENSG00000174032), UCP3 (ENSG00000175564), UCP2 (ENSG00000175567)

Protein

Protein identifiers

Solute carrier family 25 member 47 — Q6Q0C1 (reviewed: Q6Q0C1)

Alternative names: Hepatocellular carcinoma down-regulated mitochondrial carrier protein, Mitochondrial NAD(+) transporter SLC25A47

All UniProt accessions (2): Q6Q0C1, G3V374

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial NAD(+) transporter that acts as a ‘metabolic gate’ in hepatic lipogenesis. Provides NAD(+) substrate to mitochondrial SIRT3 deacetylase and enables its NAD(+)-dependent activities in mitochondrial energy metabolism. This triggers downstream activation of PRKAA1/AMPK-alpha signaling cascade that negatively regulates sterol regulatory element-binding protein (SREBP) transcriptional activities and ATP-consuming lipogenesis to restore cellular energy balance. May transport other mitochondrial metabolites having an aromatic nucleotide and phosphate groups, such as acetyl-CoA. Does not transport amino acids. The transport mechanism remains to be elucidated.

Subcellular location. Mitochondrion inner membrane. Mitochondrion outer membrane.

Tissue specificity. Specifically expressed in liver.

Induction. Down-regulated in hepatocarcinoma.

Similarity. Belongs to the mitochondrial carrier (TC 2.A.29) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6Q0C1-1	1	yes
Q6Q0C1-2	2

RefSeq proteins (2): NP_001337806, NP_997000* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002067	MCP	Family
IPR018108	MCP_transmembrane	Repeat
IPR023395	MCP_dom_sf	Homologous_superfamily
IPR050567	Mitochondrial_Carrier	Family

Pfam: PF00153

Catalyzed reactions (Rhea), 2 shown:

• NAD(+)(in) = NAD(+)(out) (RHEA:65408)
• acetyl-CoA(in) = acetyl-CoA(out) (RHEA:75039)

UniProt features (15 total): transmembrane region 6, mutagenesis site 3, repeat 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6Q0C1-F1	84.88	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (3):

Position	Phenotype
24	impaired nad(+) uptake.
188	impaired nad(+) uptake.
284	impaired nad(+) uptake.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 68 (showing top): GOBP_NUCLEOTIDE_TRANSPORT, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, UEDA_PERIFERAL_CLOCK, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOMF_NUCLEOBASE_CONTAINING_COMPOUND_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOBP_NUCLEOTIDE_TRANSMEMBRANE_TRANSPORT, GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SULFUR_COMPOUND_TRANSPORT, GOCC_MITOCHONDRIAL_ENVELOPE, HNF4_01, GOBP_PURINE_NUCLEOTIDE_TRANSPORT, chr14q32, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_ORGANELLE_INNER_MEMBRANE

GO Biological Process (3): acetyl-CoA transport (GO:0015876), NAD transmembrane transport (GO:0035352), transmembrane transport (GO:0055085)

GO Molecular Function (3): acetyl-CoA transmembrane transporter activity (GO:0008521), transmembrane transporter activity (GO:0022857), NAD transmembrane transporter activity (GO:0051724)

GO Cellular Component (4): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitochondrial membrane	2
fatty-acyl-CoA transport	1
NAD transport	1
purine-containing compound transmembrane transport	1
nucleotide transmembrane transport	1
transport	1
cellular process	1
organophosphate ester transmembrane transporter activity	1
acetyl-CoA transport	1
nucleobase-containing compound transmembrane transporter activity	1
sulfur compound transmembrane transporter activity	1
transporter activity	1
transmembrane transport	1
adenine nucleotide transmembrane transporter activity	1
NAD transmembrane transport	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle outer membrane	1
organelle inner membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

979 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC25A47	SLC25A53	Q5H9E4	478
SLC25A47	SLC25A52	Q3SY17	451
SLC25A47	FAM228A	Q86W67	417
SLC25A47	LRRN4CL	Q8ND94	393
SLC25A47	OR1F1	O43749	377
SLC25A47	SLC25A51	Q9H1U9	374
SLC25A47	KRTAP5-7	Q6L8G8	370
SLC25A47	SLC33A1	O00400	360
SLC25A47	SLC35F4	A4IF30	359
SLC25A47	SLC5A12	Q1EHB4	350
SLC25A47	PCBD2	Q9H0N5	344
SLC25A47	WDR25	Q64LD2	325
SLC25A47	NPIPB13	A6NJU9	325
SLC25A47	SLC15A2	Q16348	324
SLC25A47	JKAMP	Q9P055	313

IntAct

4 interactions, top by confidence:

A	B	Type	Score
C1QA	SLC25A47	psi-mi:“MI:0915”(physical association)	0.370
SLC25A47	DIABLO	psi-mi:“MI:0915”(physical association)	0.370
SLC25A47	RPSA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (5): MGEA5 (Affinity Capture-MS), ANKRD40 (Affinity Capture-MS), RPSAP58 (Affinity Capture-MS), DIABLO (Two-hybrid), C1QA (Two-hybrid)

ESM2 similar proteins: A0PC02, A1DI57, A2ADF7, A2R5A0, A3KPP4, G3XP90, O95847, P04633, P10861, P12242, P16260, P56500, Q01888, Q08DK7, Q0CEN9, Q17QI7, Q23125, Q29RM1, Q2UCW8, Q3KQZ1, Q3SZK0, Q4V8K4, Q505J6, Q58DS3, Q5HZE0, Q5IS35, Q5NVC1, Q5SWT3, Q5XIF9, Q6AYL0, Q6IS41, Q6J329, Q6PH61, Q6PIV7, Q6Q0C1, Q7SXW0, Q8BL03, Q8C0K5, Q8N8R3, Q9BV35

Diamond homologs: A0A0G2K309, A0A0G2K5L2, A2R5A0, A4QNX2, F1LX07, F1LZW6, F1RFX9, O43772, O75746, O89035, O97562, P16261, P22292, P27080, P32331, P38087, P90992, P97521, Q08CI8, Q08DK7, Q10248, Q1ECW7, Q21153, Q27257, Q3MHI3, Q54BM3, Q54FE6, Q54RB9, Q55E85, Q58DS3, Q5HZE0, Q5RBC8, Q5SWT3, Q6DHS9, Q6IS41, Q6J329, Q6PIV7, Q6Q0C1, Q6ZT89, Q75AH6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1085 predictions. Top by Δscore:

Variant	Effect	Δscore
14:100326207:GGA:G	donor_gain	1.0000
14:100326208:GA:G	donor_gain	1.0000
14:100326209:A:G	donor_gain	1.0000
14:100326225:GCGC:G	donor_gain	1.0000
14:100326227:GC:G	donor_gain	1.0000
14:100326229:G:GG	donor_gain	1.0000
14:100327256:T:TA	acceptor_gain	1.0000
14:100327369:GC:G	donor_gain	1.0000
14:100327371:G:GG	donor_gain	1.0000
14:100328718:T:TA	acceptor_gain	1.0000
14:100328721:TCCA:T	acceptor_loss	1.0000
14:100328722:CCA:C	acceptor_loss	1.0000
14:100328723:CA:C	acceptor_loss	1.0000
14:100328724:AGG:A	acceptor_loss	1.0000
14:100328724:AGGT:A	acceptor_gain	1.0000
14:100328725:GGT:G	acceptor_gain	1.0000
14:100328725:GGTG:G	acceptor_gain	1.0000
14:100329042:CAG:C	donor_loss	1.0000
14:100329043:AGGTG:A	donor_loss	1.0000
14:100329044:GGTGA:G	donor_loss	1.0000
14:100329045:GTGAG:G	donor_loss	1.0000
14:100329046:T:G	donor_loss	1.0000
14:100325907:C:G	donor_gain	0.9900
14:100327182:TGCTA:T	acceptor_loss	0.9900
14:100327183:GCTAG:G	acceptor_loss	0.9900
14:100327184:CTA:C	acceptor_loss	0.9900
14:100327185:TA:T	acceptor_loss	0.9900
14:100327186:A:AC	acceptor_loss	0.9900
14:100327187:G:GT	acceptor_loss	0.9900
14:100327187:GGT:G	acceptor_gain	0.9900

AlphaMissense

1934 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:100329444:G:C	K242N	0.992
14:100329444:G:T	K242N	0.992
14:100329433:G:C	D239H	0.990
14:100328758:A:C	K120N	0.988
14:100328758:A:T	K120N	0.988
14:100325831:G:C	K24N	0.987
14:100325831:G:T	K24N	0.987
14:100327254:T:C	F71L	0.987
14:100327256:T:A	F71L	0.987
14:100327256:T:G	F71L	0.987
14:100325820:G:C	D21H	0.982
14:100329547:G:A	G277R	0.982
14:100329547:G:C	G277R	0.982
14:100329392:G:A	G225D	0.981
14:100327348:G:A	G102E	0.979
14:100329412:T:A	W232R	0.979
14:100329412:T:C	W232R	0.979
14:100329434:A:C	D239A	0.979
14:100328757:A:T	K120I	0.978
14:100328939:G:C	G181R	0.978
14:100325821:A:T	D21V	0.977
14:100329442:A:G	K242E	0.977
14:100329501:T:G	C261W	0.977
14:100328770:G:C	Q124H	0.976
14:100328770:G:T	Q124H	0.976
14:100329398:C:A	A227E	0.976
14:100329452:T:C	L245P	0.976
14:100329511:A:C	S265R	0.976
14:100329513:C:A	S265R	0.976
14:100329513:C:G	S265R	0.976

dbSNP variants (sampled 300 via entrez): RS1000164580 (14:100329984 T>A), RS1000621284 (14:100329823 C>T), RS1000881128 (14:100321711 G>A), RS1000904537 (14:100326227 G>A), RS1000963451 (14:100326712 G>A,T), RS1001269635 (14:100326521 C>T), RS1001289822 (14:100330327 C>T), RS1001511958 (14:100328353 C>T), RS1001641094 (14:100324132 C>T), RS1001931125 (14:100328618 G>A,C,T), RS1001976277 (14:100322879 C>T), RS1002014406 (14:100325457 T>C), RS1002519653 (14:100329417 T>C,G), RS1002690927 (14:100325327 C>T), RS1002749080 (14:100329309 G>A,T)

Disease associations

OMIM: gene MIM:609911 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010241_70	Apolipoprotein A1 levels	6.000000e-14

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004614	apolipoprotein A 1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Mitochondrial amino acid transporter subfamily

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
bisphenol A	decreases methylation	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	increases methylation	1
Atrazine	increases expression	1
Diazinon	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Testosterone	increases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Tobacco Smoke Pollution	increases expression	1
Toluene	decreases methylation, increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer